Triaziquone

Triaziquone

SCHEMBL6563614

CSC.O=C1C=C(N2CC2)C(=O)C(N2CC2)=C1N1CC1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
HTT P42858 2/20 0.44
TP53 P04637 1/20 0.44
STAT3 P40763 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
DNMT1 P26358 1/20 0.43
ALDH1A1 P00352 1/20 0.36
TDP2 O95551 3/20 0.36
NSD2 O96028 3/20 0.36
APAF1 O14727 2/20 0.36
HKDC1 Q2TB90 2/20 0.36
KMT2A Q03164 2/20 0.34
ATG4B Q9Y4P1 2/20 0.34
LMNA P02545 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
GALK1 P51570 1/20 0.34
BLM P54132 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triaziquone SCHEMBL8303 0.92 DNMT1 (0.48) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL7783197 0.90 MAPT (0.46) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL149876 0.90 MAPT (0.46) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL8482641 0.90 DNMT1 (0.47) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL1538515 0.90 DNMT1 (0.47) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL7738777 0.90 DNMT1 (0.47) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL8993238 0.90 DNMT1 (0.47) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL6000230 0.90 DNMT1 (0.47) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL5054475 0.90 DNMT1 (0.47) MAPTHTTTP53STAT3SMN1; SMN2
Triaziquone SCHEMBL3101456 0.90 DNMT1 (0.47) MAPTHTTTP53STAT3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0933993-A4 SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS BIOCRYST PHARM INC (US) 2004-09-08 EP disclosed
EP-0933993-A1 SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS BIOCRYST PHARMACEUTICALS INC. (US) 1999-08-11 EP disclosed
EP-0817642-A1 $g(b)-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF BIOLOGICALLY ACTIVE PEPTIDES OR PROTEINS MOLECUMETICS, LTD. (US) 1998-01-14 EP disclosed
EP-0815123-A1 $g(b)-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS MOLECUMETICS, LTD. (US) 1998-01-07 EP disclosed
WO-1997047194-A1 SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 1997-12-18 WO disclosed
WO-1996030396-A1 β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS MOLECUMETICS LTD. (US) 1996-10-03 WO disclosed
WO-1996030035-A1 β-SHEET MIMETICS AND USE THEREOF AS INHIBITORS OF BIOLOGICALLY ACTIVE PEPTIDES OR PROTEINS MOLECUMETICS LTD. (US) 1996-10-03 WO disclosed